1. Quality control in the regulation of pharmaceuticals

   • Alan Maynard

   Editorial 17 September 2012 Pages: 421 - 422

2. Willingness to pay for a QALY

   • Dorte Gyrd-Hansen

   Current Opinion 17 September 2012 Pages: 423 - 432

3. Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder

   • Ellen W. Freeman

   Current Opinion 17 September 2012 Pages: 433 - 444

   

4. Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems?

   • Adam La Caze

   Commentary 17 September 2012 Pages: 445 - 447

5. Valuing patient and caregiver time

   • Jennifer E. Tranmer
   • Denise N. Guerriere
   • Peter C. Coyte

   Review Article 17 September 2012 Pages: 449 - 459

   

6. The health-related quality of life and economic burden of constipation

   • Cheryl Dennison
   • Manishi Prasad
   • Karin Coyne

   Review Article 17 September 2012 Pages: 461 - 476

   

7. Economic considerations in the prescribing of third-generation antidepressants

   • Stuart Montgomery
   • John J. Doyle
   • Christopher R. McBurney

   Review Article 17 September 2012 Pages: 477 - 491

   

8. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy

   • Lucie Blais
   • Odile Sheehy
   • Jacques LeLorier

   Original Research Article 17 September 2012 Pages: 493 - 503

   

9. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy

   • Ernst Berndt
   • Joel Kallich
   • John Glaspy

   Original Research Article 17 September 2012 Pages: 505 - 514

   

10. Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia

    • Kim Dalziel
    • Ali Round
    • Ken Stein

    Original Research Article 17 September 2012 Pages: 515 - 526

    

11. On pharmacogenomics and cost-effectiveness analysis at the individual level

    • Mohan V. Bala
    • Gary A. Zarkin

    Correspondence 17 September 2012 Pages: 527 - 527